Russian group «Mir-Pharm» to be located in the Special Economic Zone "Kaluga"
On June 30, 2016 the Governor of Kaluga region Anatoly Artamonov and the general director of the OOO «Mir-Pharm» Iskandar Ismaguilov signed a Memorandum of understanding for the investment project of building a plant to produce high-tech pharmaceutical substances and solid dosage forms.
On June 30, 2016 the Governor of Kaluga region Anatoly Artamonov and the general director of the OOO «Mir-Pharm» Iskandar Ismaguilov signed a Memorandum of understanding for the investment project of building a plant to produce high-tech pharmaceutical substances and solid dosage forms.
It is a preliminary agreement for the construction of a new pharmaceutical production facility in the Industrial Special Economic Zone "Kaluga". The company opted for an area located in Borovsk district and contiguous to Moscow region.
The investment will amount to about RUR 450 million. The facility will provide about 120 jobs and will produce 500 million tablets and 100 million capsules a year. Currenty the products of the Group «Mir-Pharm» are marketed not only in Russia but also in a number of the former Soviet republics: Azerbaijan, Belarus, Ukraine, Moldova, Kazakhstan, Kyrgyzstan. Several medicines produced by the company are on the list of the vital and most important drugs of the Russian Federation.
The group of companies «Mir-Pharm» (ООО «Mir-Pharm», ZАО «Obninsk Chemical and Pharmaceutical Company») began its activities in 2001 on the premises of the Experimental Unit of the Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre of the Ministry of Health of Russian Federation. Today the Group of companies «Mir-Pharm» focuses on manufacturing of pharmaceutical (chemical) substances and finished dosage forms, used in various fields of medicine such as gynecology, neurology, cardiology, transplantation, surgery, anesthesiology and resuscitation. Since its creation the company is aimed at implementing the import substitution program, consisting in replacing imported high-priced medicines by their Russian affordable analogs of equal quality.
"In Kaluga region we shall produce drugs for different purposes, including the central nervous system, cerebral circulation, cardiovascular system. Special consideration will be given to the development and production of obstetrics and gynecology products. The facility is envisaged for a complete production cycle, which will make it possible to develop novel drugs manufacturing methods. The first phase of the facility is to be commissioned in three years,"- commented Iskandar Ismaguilov.
Anatoly Artamonov highlighted that in this instance the investor is a company that had been successfully working in Obninsk for more than 15 years, which is most significant. The intentions of the company's management to bring import subtituting medicines to market and to increase the production volumes are highly laudable.
"Kaluga pharmaceutical cluster is developing steadily. It manifests itself not only in the creation of new businesses, but also in the growing localisation rate and the proliferation of cooperative ties. Now Kaluga pharmaceutical cluster brings together 63 members. The company «Mir-Pharm» is provided with research resources, which can reinforce the cluster's standing in the Russian market," - pointed out Anatoly Artamonov.
In 2015 the company brought to market 3 import substituting generics made from the substances produced by the ZАО «Obninsk Chemical and Pharmaceutical Company». One of them is the first world's generic of the agent Prucalopride. Eight more new agents are to be registered in 2016, including much-needed gynecologic agents Atosiban and Carbetocin, which would be the first generics of these brand name drugs in Russia. Currently there are about 30 new medicines (including 8 brand names) under study or in registration process. They will be used in gastroenterology, gynecology, urology, reanimatology, neurology, oncology. The innovative achievements of «Mir-Pharm» are confirmed by the fact that for the last four years it has been on the list of the best of Russia's fast growing high-tech companies national rating "TechUp".
For information:
The portfolio of Kaluga region pharmaceutical companies contain more than 109 products, more than 20 pharmaceutical products being in the registration process and several dozen in prospective study. More than 80% of the Cluster production are finished pharmaceutical products. In 2015 the production value amounted to RUR 19 billion.
